JP2021526845A5 - - Google Patents

Info

Publication number
JP2021526845A5
JP2021526845A5 JP2021500908A JP2021500908A JP2021526845A5 JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5 JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
pharmaceutical composition
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526845A (ja
JP7534281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/069035 external-priority patent/WO2020012038A1/en
Publication of JP2021526845A publication Critical patent/JP2021526845A/ja
Publication of JP2021526845A5 publication Critical patent/JP2021526845A5/ja
Priority to JP2024125676A priority Critical patent/JP2024160275A/ja
Application granted granted Critical
Publication of JP7534281B2 publication Critical patent/JP7534281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500908A 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療 Active JP7534281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125676A JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862697719P 2018-07-13 2018-07-13
US62/697,719 2018-07-13
US201962848861P 2019-05-16 2019-05-16
US62/848,861 2019-05-16
PCT/EP2019/069035 WO2020012038A1 (en) 2018-07-13 2019-07-15 Trogocytosis-mediated therapy using cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125676A Division JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Publications (3)

Publication Number Publication Date
JP2021526845A JP2021526845A (ja) 2021-10-11
JP2021526845A5 true JP2021526845A5 (https=) 2022-07-21
JP7534281B2 JP7534281B2 (ja) 2024-08-14

Family

ID=67441085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500908A Active JP7534281B2 (ja) 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Country Status (5)

Country Link
US (1) US20240254252A1 (https=)
EP (1) EP3820890A1 (https=)
JP (2) JP7534281B2 (https=)
MA (1) MA53123A (https=)
WO (1) WO2020012038A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230272105A1 (en) * 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
WO2023192321A2 (en) * 2022-03-28 2023-10-05 Vygen-Bio, Inc. Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Cd38抗體及其用途
US20250296989A1 (en) * 2024-03-20 2025-09-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
BR112015022855A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EA037548B1 (ru) 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN109563511A (zh) 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN117887794A (zh) 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗体のインビトロ糖鎖工学における酵素の再使用
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작

Similar Documents

Publication Publication Date Title
US11498963B2 (en) Anti-LILRB antibodies and their use in detecting and treating cancer
JP2021524276A5 (https=)
JP2021526845A5 (https=)
Adler et al. Therapeutic antibodies against cancer
KR101843807B1 (ko) 암의 치료 및/또는 예방을 위한 의약품
CA2788545C (en) Pharmaceutical composition for treating and/or preventing cancer
JP7753186B2 (ja) 抗pd-1抗体およびその医学的使用
KR102115143B1 (ko) 항 fgfr2 항체
CN121021694A (zh) 结合cd123的多肽及其用途
HUE030103T2 (en) A pharmaceutical composition for the treatment and / or prevention of cancer
JP2022525071A (ja) Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法
TW201642897A (zh) Her2結合劑治療
JP2019151635A (ja) 抗fgfr2抗体と他剤の組合せ
CN115135344A (zh) 在疗法中使用的抗体
WO2022179507A1 (en) Methods of preventing, alleviating or treating tumors
AU2021378152A1 (en) COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
JP2023089273A (ja) 自己免疫疾患治療用抗体
KR20230135637A (ko) 새로운 활성을 갖는 hhla2 결합제
CN112041346B (zh) 用于与抗pd-1抗体组合的抗cd137抗体
Wu et al. Development and characterization of 4A7: a high-affinity monoclonal antibody targeting Claudin18. 2
WO2024109657A1 (zh) 抗ccr8抗体及其用途
CN114616245B (zh) 一种抗cd38的抗体及其用途
JP2020507576A (ja) Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP4523702A1 (en) Combination of antibody-drug conjugate and anti-sirpalpha antibody
JP7384668B2 (ja) 細胞傷害性t細胞枯渇用組成物